Stay updated on Daratumumab for AML/High-Risk MDS Clinical Trial
Sign up to get notified when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.

Latest updates to the Daratumumab for AML/High-Risk MDS Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe record describes a phase 2 study of daratumumab for relapsed or refractory blood cancers, including its eligibility criteria, treatment plan, outcomes, and study results. It also shows that the study was terminated early for lack of efficacy and is no longer recruiting.SummaryDifference45%

- Check18 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA notice was added announcing NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe ClinicalTrials.gov footer revision indicator changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1; the page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check46 days agoChange DetectedThe study record page displays a 403 Forbidden message and a Home link in its main content area.SummaryDifference0.5%

Stay in the know with updates to Daratumumab for AML/High-Risk MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.